The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. Management is already contemplating whether the drugs will be used off-label.

Patient materials for Shire’s ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA’s Division of Drug Marketing, ...

Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch, with "closely aligned" consumer ...

The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding concomitant use of strong and moderate CYP3A4 inhibitors or inducers.

The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor agonist, for the treatment of attention-deficit hyperactivity ...

About INTUNIV Once-daily INTUNIV is the first non-scheduled selective alpha-2A agonist for the treatment of ADHD in children and adolescents aged 6 to 17.

Shire faces a delay in getting its new attention-deficit hyperactivity disorder drug Intuniv approved in the USA but the company is still confident of launching the treatment across the pond before ...

Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...

INTUNIV, a once-daily formulation of guanfacine, provides a controlled, steady delivery of drug throughout the day and evening with a delivery system that minimizes the fluctuations between peak ...